Maddyness

Biotech Base Genomics raises £8.8M in seed funding to boost cancer research

Comments
Share :
Up
Previous part
1 —
Next part
Down
Maddyness
Up
Menu
Part 1
Down
Finance

Biotech Base Genomics raises £8.8M in seed funding to boost cancer research

Credits: Unsplash © Adrien Converse
54 - trending  |  
Comments
By Maddyness - 05 June 2020 / 07H30 - Updated 15 June 2020

The seed funding round was led by Oxford Sciences Innovation with participation from genomics and oncology experts. With this new investment, Base Genomics intends to develop its epigenetic technology for early and sensitive detection of cancer from liquid biopsy.

Base Genomics will also progress the development of its TAPS technology, initially focusing on developing a blood test for early-stage cancer and minimal residual disease. Expert in epigenetics, the company has launched with a team of leading scientists and clinicians to set a new gold standard in DNA methylation detection.

DNA methylation is an epigenetic mechanism involved in gene regulation and has been shown to be one of the most promising biomarkers for detecting cancer through liquid biopsy. The existing industry standard for mapping DNA methylation degrades DNA and reduces sequence complexity, however, limiting scientific discovery and clinical sensitivity. Base Genomics’ new technology, TAPS, overcomes these issues and generates significantly more information from a given sample, creating new opportunities in research and the clinic.

“In order to realize the potential of liquid biopsies for clinically meaningful diagnosis and monitoring, sensitive detection and precise quantification of circulating tumour DNA is paramount. Current approaches are not fit for purpose to achieve this, but Base Genomics has developed a game-changing technology which has the potential to make the sensitivity of liquid biopsies a problem of the past.” – Anna Schuh, CMO of Base Genomics

First developed at Ludwig Institute for Cancer Research Branch at the University of Oxford, TAPS is a novel chemical reaction that converts methylated cytosine to thymine under mild conditions. Unlike the industry-standard technology, bisulfite sequencing, TAPS does not degrade DNA, meaning that significantly more DNA is available for sequencing. TAPS also better retains sequence complexity, cutting sequencing costs in half and enabling simultaneous epigenetic and genetic analysis.

“Genomic technologies with the power, simplicity and broad applicability of TAPS come along very infrequently. It has the potential to have an impact on epigenetics similar to that which Illumina’s SBS chemistry had on Next Generation Sequencing.” – Vincent Smith, CTO of Base Genomics

Base Genomics is led by a highly experienced team of scientists and clinicians, including Dr Vincent Smith, a world-leader in genomic product development and former Illumina VP; Dr Anna Schuh, Head of Molecular Diagnostics at the University of Oxford and Principal Investigator on over 30 clinical trials; Drs Chunxiao Song and Yibin Liu, co-inventors of TAPS at the Ludwig Institute for Cancer Research, Oxford; and Oliver Waterhouse, previously an Entrepreneur in Residence at Oxford Sciences Innovation and founding team member at Zinc VC.

“The ability to sequence a large amount of high-quality epigenetic information from a simple blood test could unlock a new era of preventative medicine. In the future, individuals will not just be sequenced once to determine their largely static genetic code, but will be sequenced repeatedly over time to track dynamic epigenetic changes caused by age, lifestyle, and disease.” – Oliver Waterhouse, founder and CEO of Base Genomics

Read also
By

Maddyness

05 June 2020 / 07H30
Updated 15 June 2020
Business
Menu
Entrepreneurs
Menu
Finance
Menu
Innovation
Menu
Technology
Menu
Agenda
Calendar
MaddyEvent
MaddyEvent
MaddyStudio
MaddyStudio
Search
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Most viewed articles
Newsletter
About
Legal Information
Search
Our services
Categories
Maddynews
Hmm ... There's a problem :(
Maddyness

Comme vous le savez, Maddyness est à la pointe de l'innovation.
Malheureusement il semble que votre navigateur ne le soit pas encore...

Pour une bonne expérience de navigation
(et être au top de la modernité) pensez à passer sur :
Chrome
Chrome
Safari
Safari
Firefox
Firefox
Edge
Edge